Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Up 2,750.0% in April

Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 5,700 shares, an increase of 2,750.0% from the March 31st total of 200 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 9,800 shares, the short-interest ratio is currently 0.6 days.

Ipsen Stock Down 1.9 %

Ipsen stock traded down $0.54 during trading hours on Friday, hitting $27.90. The stock had a trading volume of 312 shares, compared to its average volume of 6,125. The stock's 50-day moving average price is $28.51 and its 200-day moving average price is $29.43. Ipsen has a 12-month low of $25.11 and a 12-month high of $34.06.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Ipsen in a report on Wednesday, April 2nd.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.